Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 5
Submit an article Journal homepage
479
Views
3
CrossRef citations to date
0
Altmetric
Author's View

BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system

Geoffrey D. ClappDepartment of Mathematics and Center for Scientific Computation and Mathematical Modeling (CSCAMM), University of Maryland, College Park, MD, USA
,
Thomas LepoutreInria, and Université de Lyon, Université Claude Bernard Lyon, CNRS UMR 5208, Institute Camille Jordan, Villeurbanne Cedex, France
,
Franck E. NicoliniHematology Department 1G, Center Hospatlier Lyon, Sud, Pierre-Bénite, France and INSERM U1052, CRCL, Center Léon Bérard, Lyon, France
&
Doron LevyDepartment of Mathematics and Center for Scientific Computation and Mathematical Modeling (CSCAMM), University of Maryland, College Park, MD, USACorrespondence[email protected]
Article: e1122159 | Received 12 Nov 2015, Accepted 14 Nov 2015, Published online: 29 Apr 2016

References

  • An X, Tiwari AK, Sun Y, Ding PR, Ashby CR, Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leukemia Res 2010; 34:1255–68; PMID:20537386; http://dx.doi.org/10.1016/j.leukres.2010.04.016
  • Kim P, Lee P, Levy D. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PloS Comp Biol 2008; 4(6):e1000095; PMID:18566683; http://dx.doi.org/10.1371/journal.pcbi.1000095
  • Michor F, Hughes F, Iwasa Y, Branford S, Shah N, Sawyers C, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature 2005; 435(30):1267–70; PMID:15988530; http://dx.doi.org/10.1038/nature03669
  • Roeder I, Horn M, Glauche I, Hochhaus A, Mueller M, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nature Med 2006; 12(10):1181–4; PMID:17013383; http://dx.doi.org/10.1038/nm1487
  • Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood 2011; 118(6):1622–31; PMID:21653938; http://dx.doi.org/10.1182/blood-2011-02-339267
  • Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D et al. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86(5):2041–50; PMID:7655033
  • Talpaz M, Hehlmann R, Quintás-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia 2013; 27:803–12; PMID:23238589; http://dx.doi.org/10.1038/leu.2012.313
  • Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet S et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11(11):1029–35; PMID:20965785; http://dx.doi.org/10.1016/S1470-2045(10)70233-3
  • Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122:515–22; PMID:23704092; http://dx.doi.org/10.1182/blood-2013-02-483750
  • Clapp G, Lepoutre T, El Cheikh R, Bernard S, Ruby J, Labussiere-Wallet H. Implication of the autologous immune system in BCR-ABL transcript variations in chronic myelogenous leukemia patients treated with imatinib. Cancer Res 2015; 75(19):4053–62; PMID:26359456; http://dx.doi.org/10.1158/0008-5472.CAN-15-0611

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.